These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19000475)

  • 1. [New CCR5 inhibitor antiretroviral drugs and integrase inhibitors].
    Moreno Cuerda VJ; Rubio García R; Barros Aguado C; Morales Conejo M
    Rev Clin Esp; 2008 Oct; 208(9):463-6. PubMed ID: 19000475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New antiretroviral drug classes in HIV therapy].
    Lehmann C; Meuer K; Kümmerle T; Fätkenheuer G
    MMW Fortschr Med; 2009 Apr; 151(18):64-6. PubMed ID: 19769081
    [No Abstract]   [Full Text] [Related]  

  • 4. A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probably related to integrase inhibitor use.
    Degli Antoni A; Weimer LE; Manfredi R; Fragola V; Ferrari C
    West Indian Med J; 2012 Dec; 61(9):932-6. PubMed ID: 24020238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Features and the method of application of a CCR5 antagonist, a new integrase inhibitor].
    Katanaga H
    Nihon Naika Gakkai Zasshi; 2009 Nov; 98(11):2802-8. PubMed ID: 22462133
    [No Abstract]   [Full Text] [Related]  

  • 6. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
    Hughes A; Barber T; Nelson M
    J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
    Yost R; Pasquale TR; Sahloff EG
    Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical pharmacokinetic of maraviroc].
    Peytavin G
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S12-6. PubMed ID: 18455057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients.
    Gonzalez-Serna A; Genebat M; Ruiz-Mateos E; Leal M
    Drug Des Devel Ther; 2016; 10():353-4. PubMed ID: 26848259
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel HIV treatment approved.
    Groeschen HM
    Am J Health Syst Pharm; 2007 Sep; 64(18):1886. PubMed ID: 17823091
    [No Abstract]   [Full Text] [Related]  

  • 11. Antiretroviral treatment update from the 17th International AIDS Conference.
    Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
    AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
    [No Abstract]   [Full Text] [Related]  

  • 12. [Introduction. A brief history of AIDS].
    Alcamí J
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():1-4. PubMed ID: 19133214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR5 antagonism in HIV infection: current concepts and future opportunities.
    Wilkin TJ; Gulick RM
    Annu Rev Med; 2012; 63():81-93. PubMed ID: 22034870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maraviroc approved for use in treatment-experienced CCR5-tropic HIV-1.
    AIDS Alert; 2009 Jan; 24(1):10-2. PubMed ID: 19209462
    [No Abstract]   [Full Text] [Related]  

  • 15. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection.
    Caldwell DJ; Evans JD
    Expert Opin Pharmacother; 2008 Dec; 9(18):3231-42. PubMed ID: 19040343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in-depth look at the challenges of prescribing maraviroc.
    Edmunds-Ogbuokiri T
    HIV Clin; 2008; 20(3):9-11. PubMed ID: 18814378
    [No Abstract]   [Full Text] [Related]  

  • 19. [Maraviroc: clinical trials results].
    Chidiac C; Katlama C; Yeni P
    Med Mal Infect; 2008 Mar; 38 Suppl 1():S17-23. PubMed ID: 18455058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary effects of treatment with maraviroc and other CCR5 antagonists. Potential impact of the CCR5 blocker].
    Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():23-7. PubMed ID: 19133218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.